IMMUNOCLIN CORP (IMCL)

0.16
OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)
'Fast Money' Recap: Sell the Big Moves

'Fast Money' Recap: Sell the Big Moves

The trading panel says tech is still good, but don't forget to take profits.

Health Winners & Losers: Ligand

Health Winners & Losers: Ligand

Ligand soars on a promising FDA panel vote.

'Fast Money' Portfolios of the Week

'Fast Money' Portfolios of the Week

Here are some of the stocks the 'Fast Money' crew has been talking about lately.

Erbitux Closer to Expanded Use in EU

Erbitux Closer to Expanded Use in EU

A European advisory committee recommends the drug be approved for use as a first-line treatment for colorectal cancer.

Bristol Inks Deal for Kosan Biosciences

Bristol Inks Deal for Kosan Biosciences

The drugmaker will pay $5.50 a share for the biotech company, a $190 million deal that will enhance its cancer drug portfolio.

ImClone Investors Await Key Cancer Data

ImClone Investors Await Key Cancer Data

The much-anticipated overall survival data for lung cancer Erbitux will be released June 1.

Health Winners & Losers: Celgene

Health Winners & Losers: Celgene

Celgene climbs on a bullish analyst note.

Genentech's Avastin Passes Key Safety Test

Genentech's Avastin Passes Key Safety Test

The company shared the news late Thursday and said data will now be available a year earlier than expected.

Health Winners & Losers: Geron

Health Winners & Losers: Geron

Geron takes back some of the previous day's big loss.

Health Winners & Losers: Abbott

Health Winners & Losers: Abbott

Abbott Labs climbs on new data from its Spirit III trial for its Xience V stent.

ImClone 'Eager' for Erbitux Data Release

ImClone 'Eager' for Erbitux Data Release

The biotech stock has fallen ahead of ASCO on doubts about the FLEX study, but management remains bullish.

Health Winners & Losers: Isis

Health Winners & Losers: Isis

The biotech rises on a narrowed first-quarter loss.

ASCO Abstract Preview: ImClone, Genentech

ASCO Abstract Preview: ImClone, Genentech

The American Society of Clinical Oncology, for the first time, is making research abstracts freely available to everyone ahead of the cancer drug confab. Here's a cheat sheet.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

What to expect when ImClone presents the latest Erbitux data at ASCO in June.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Progenics climbs on bullish anticipation for Relistor.

Charges Weigh on Schering Profit

Charges Weigh on Schering Profit

But factoring out acquisition costs, the drugmaker beats Wall Street's first-quarter estimates.

Genzyme Beats Earnings Targets

Genzyme Beats Earnings Targets

The biotech company posts first-quarter profit and revenue that just exceed expectations.

Genzyme Cuts Outlook After FDA Setback

Genzyme Cuts Outlook After FDA Setback

U.S. regulators say Myozyme produced at the 160-liter bioreactor scale and the same drug made at the 2,000-liter scale should be classified as two different products.

European Trial Slows Genentech's Avastin

European Trial Slows Genentech's Avastin

The failure shouldn't immediately threaten revenue, but could make doctors re-evaluate use.

How to Review Biotech Clinical Data

How to Review Biotech Clinical Data

If you can spot red flags in data presentations, you can avoid getting suckered into biotech money traps.

Pfizer, Avant Ink R&D Deal for Cancer Vaccine

Pfizer, Avant Ink R&D Deal for Cancer Vaccine

The Big Pharma will assume all development costs for CDX-110 and pay royalties to the biotech on the sales if the drug's approved.

Fast Money 'Pops and Drops': Amgen Hangs Tough

Fast Money 'Pops and Drops': Amgen Hangs Tough

The panel says the pharma company was right to stand up for its anemia patent.

Altucher's Blog Watch: April 7

Altucher's Blog Watch: April 7

Is the lower paid clicks issue a problem for Google, and the first bathroom in America.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Baxter rises on plans for a $2 billion buyback.

Wednesday's Analysts' Upgrades, Downgrades

Wednesday's Analysts' Upgrades, Downgrades

See who made what calls.

Altucher's Blog Watch: March 12

Is there a plunge protection team boosting the markets, and what happens after large Dow moves?

Checking the Vital Signs of Healthcare ETFs

Checking the Vital Signs of Healthcare ETFs

How are healthcare, pharmaceutical and biotech ETFs holding up in the market turmoil?

Biotech Notebook: Genentech, Exact Sciences

Biotech Notebook: Genentech, Exact Sciences

Avastin's approval could spark Genentech to boost earnings guidance.

Get a Head Start on Biotech's ASCO Confab

Get a Head Start on Biotech's ASCO Confab

This year's meeting is particularly huge, since it marks the first time abstracts will be released to all in advance.